Zila divests Zilactin
This article was originally published in The Tan Sheet
Executive Summary
Phoenix-based company sells its Zilactin brand of OTC lip and oral care products to Columbus, Ind.-based Blairex Laboratories for $10.3 mil. "plus agreed upon working capital adjustments," Zila announces June 27. The line includes Zilactin and Zilactin-B (benzocaine), both marketed for the treatment of cold sores, canker sores and fever blisters. The divestiture of the "non-strategic asset" is in line with Zila's plan to focus on "preventive healthcare technologies" such as its Ester-C and Ester-E supplement lines, according to the firm...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.